Related Experiment Video
Updated: Feb 28, 2026
08:01
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
2.3K
Malignant Mesothelioma: Time to Translate?
Andrea Napolitano1, Michele Carbone1
1Department of Thoracic Oncology, University of Hawai i Cancer Center, 96826 Honolulu, HI, USA.
Trends in Cancer
|June 13, 2017
Summary
Malignant mesothelioma, a cancer linked to asbestos, shows genetic advances like BAP1 mutations. Clinical translation of these findings needs more collaborative research for better treatments.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant mesothelioma is an aggressive cancer strongly linked to asbestos exposure.
- Understanding the genetic and molecular basis of mesothelioma is crucial for developing effective treatments.
Purpose of the Study:
- To review recent advancements in the genetics and molecular biology of malignant mesothelioma.
- To discuss the translational relevance of these discoveries for therapeutic development.
Main Methods:
- Review of current literature on mesothelioma genetics and molecular pathways.
- Analysis of identified germline and somatic mutations, including BRCA1 associated protein-1 (BAP1).
- Examination of genome-wide pathway characterization relevant to mesothelioma.
Main Results:
- Discovery of germline and somatic mutations in BAP1 in mesothelioma patients.
- Genome-wide characterization of altered pathways provides potential therapeutic targets.
- Despite molecular progress, clinical translation of findings has been slow.
Conclusions:
- Significant progress has been made in understanding mesothelioma's molecular landscape.
- Targeting identified pathways and mutations holds promise for novel therapies.
- Enhanced cooperative research is essential to accelerate clinical translation from bench to bedside.
